DPP4 and type 2 diabetes mellitus: Mudgil et al. (81) hydrolysed quinoa protein using food-grade enzymes, identified 136 peptides, 35 of which were predicted as potentially bioactive peptides (BAPs) based on the Peptide Ranker score, and have high potential for inhibition of DPP-IV, AG, and ACE, DPP-IV inhibition is a key target in the treatment of T2DM, and DPP-IV inhibitors were among the first oral hypoglycaemic agents prospectively designed as glucose-lowering agents.